# Relay Therapeutics, Inc. (RLAY) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_a459773bbb5716a09e1e · retrieved 2026-08-12T06:58:47.060Z

## Overview
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, with lead program zovegalisib, a mutant-selective PI3K-alpha inhibitor in Phase 3 clinical trials for HR+/HER2- metastatic breast cancer.

Relay Therapeutics, Inc. amended its common stock sales agreement with TD Securities (USA) LLC on August 6, 2026, increasing the at-the-market (ATM) offering program size from $250,000,000 to $462,978,049. As of the filing date, the company had sold approximately $162,978,049 of shares under the original agreement. The amendment authorizes the offer and sale of up to $212,978,049 in additional shares of common stock through TD Cowen as sales agent, pursuant to a new prospectus supplement filed on August 6, 2026. TD Cowen will receive compensation of up to 3.0% of gross proceeds from share sales.

## Terms
- Counterparty: TD Securities (USA) LLC · Deal value: $213.0M · Consideration: stock

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001193125-26-338013): 8-K - Relay Therapeutics, Inc. — *Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, with lead program zovegalisib, a mutant-selective PI3K-alpha inhibitor in Phase 3 clinical trials for HR+/HER2- metastatic breast cancer.* Relay Therapeutics, Inc. amended its common stock sales agreement with TD Securities (USA) LLC on August 6, 2026, increasing the at-the-market (ATM) offering program size from $250,000,000 to $462,978,049. As of the filing date, the company had sold approximately $162,978,049 of shares under the original agreement. The amendment authorizes the offer and sale of up to $212,978,049 in additional shares of common stock through TD Cowen as sales agent, pursuant to a new prospectus supplement filed on August 6, 2026. TD Cowen will receive compensation of up to 3.0% of gross proceeds from share sales.
  https://www.sec.gov/Archives/edgar/data/1812364/0001193125-26-338013.txt

## Citations
- 0001193125-26-338013 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526338013